Scott, Jack D <br/><br/>
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.  [electronic resource] 

 -  Journal of medicinal chemistry  04 2017 
 - 2983-2992 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1520-4804 
<br/><br/><label>Standard No.: </label>10.1021/acs.jmedchem.7b00045  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Brain--metabolism<br/>Enzyme Inhibitors--administration & dosage<br/>Humans<br/>Indazoles--administration & dosage<br/>Leucine-Rich Repeat Serine-Threonine Protein Kinase-2--antagonists & inhibitors<br/>Male<br/>Molecular Docking Simulation<br/>Parkinson Disease--drug therapy<br/>Rats<br/>Rats, Wistar